ReviewComputational and structural biotechnology journal2025
The role of super-enhancer-driven lncRNAs in cancer.
Review in Computational and structural biotechnology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- An Energy Model Based on Molecular Structure for Predicting Histone Modification Levels at lncRNA Promoter Regions in HepG2 Cells.International journal of molecular sciences · 2026Article
- Hypoxic Endothelial-Cell-Derived Exosomal lnc-DKK3 Reprograms Tumor-Associated Macrophages via USP47/PD-L1/RelA Axis to Promote Glioma Progression.Research (Washington, D.C.) · 2026Article
- LncRCD: A Comprehensive Database for Pan-Cancer Characterization of lncRNAs Related to 12 Regulated Cell Death Types.Computational and structural biotechnology journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, the global burden of cancer has grown substantially, yet available treatments and clinical outcomes remain inadequate. Accordingly, research into novel therapeutic targets for cancer has become a major focus. Super-enhancers (SEs), which are clusters of multiple enhancers, represent essential epigenetic oncogenic factors that are critical for maintaining cancer cell identity. Moreover, SE-driven long non-coding RNAs (lncRNAs) play a crucial regulatory role in tumor initiation and progression. Targeting cancer-specific SE-driven lncRNAs can slow tumor development and offer a novel strategy for cancer treatment. This review first outlines the characteristics of SEs, including their relevance to phase separation (PS) and the core transcriptional regulatory circuitry (CRC). It then describes the fundamental characteristics, intracellular localization, and functions of SE-driven lncRNAs, with emphasis on the analytical methods for these lncRNAs and their roles in tumors. Finally, the review highlights the clinical applications of existing SE inhibitors in oncology and their potential for targeting SE-driven lncRNAs, aiming to advance translational research in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.